DK1342410T3 - Anvendelse af en galaninagonist til fremstilling af et medikament til forbedring af hukommelse og andre kognitive funktioner - Google Patents
Anvendelse af en galaninagonist til fremstilling af et medikament til forbedring af hukommelse og andre kognitive funktionerInfo
- Publication number
- DK1342410T3 DK1342410T3 DK02028584.7T DK02028584T DK1342410T3 DK 1342410 T3 DK1342410 T3 DK 1342410T3 DK 02028584 T DK02028584 T DK 02028584T DK 1342410 T3 DK1342410 T3 DK 1342410T3
- Authority
- DK
- Denmark
- Prior art keywords
- galanin
- drug
- manufacture
- treatment
- cognitive functions
- Prior art date
Links
- 101800002068 Galanin Proteins 0.000 title abstract 6
- 102000019432 Galanin Human genes 0.000 title abstract 5
- SLZIZIJTGAYEKK-CIJSCKBQSA-N molport-023-220-247 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CNC=N1 SLZIZIJTGAYEKK-CIJSCKBQSA-N 0.000 title abstract 5
- 239000000556 agonist Substances 0.000 title abstract 2
- 230000003920 cognitive function Effects 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 230000036407 pain Effects 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010002091 Anaesthesia Diseases 0.000 abstract 1
- 208000028389 Nerve injury Diseases 0.000 abstract 1
- 206010036832 Prolactinoma Diseases 0.000 abstract 1
- 230000037005 anaesthesia Effects 0.000 abstract 1
- 238000001949 anaesthesia Methods 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000019771 cognition Effects 0.000 abstract 1
- 238000011813 knockout mouse model Methods 0.000 abstract 1
- 210000005036 nerve Anatomy 0.000 abstract 1
- 230000008764 nerve damage Effects 0.000 abstract 1
- 208000005877 painful neuropathy Diseases 0.000 abstract 1
- 208000030153 prolactin-producing pituitary gland adenoma Diseases 0.000 abstract 1
- 230000008929 regeneration Effects 0.000 abstract 1
- 238000011069 regeneration method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0312—Animal model for Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0356—Animal model for processes and diseases of the central nervous system, e.g. stress, learning, schizophrenia, pain, epilepsy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Environmental Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Plant Pathology (AREA)
- Obesity (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9615551.0A GB9615551D0 (en) | 1996-07-24 | 1996-07-24 | Galanin |
| GBGB9623869.6A GB9623869D0 (en) | 1996-11-15 | 1996-11-15 | Galanin |
| EP97932939A EP0918455B1 (en) | 1996-07-24 | 1997-07-24 | Use of galanin to repair nerve damage |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1342410T3 true DK1342410T3 (da) | 2010-05-31 |
Family
ID=26309752
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK02028584.7T DK1342410T3 (da) | 1996-07-24 | 1997-07-24 | Anvendelse af en galaninagonist til fremstilling af et medikament til forbedring af hukommelse og andre kognitive funktioner |
| DK97932939T DK0918455T3 (da) | 1996-07-24 | 1997-07-24 | Anvendelse af galanin til reparation af nerveskader |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK97932939T DK0918455T3 (da) | 1996-07-24 | 1997-07-24 | Anvendelse af galanin til reparation af nerveskader |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20030009777A1 (da) |
| EP (2) | EP0918455B1 (da) |
| JP (1) | JP2000516212A (da) |
| AT (2) | ATE457125T1 (da) |
| AU (1) | AU3630297A (da) |
| DE (2) | DE69739760D1 (da) |
| DK (2) | DK1342410T3 (da) |
| ES (2) | ES2340984T3 (da) |
| GB (1) | GB2331301C (da) |
| PT (2) | PT918455E (da) |
| WO (1) | WO1998003059A1 (da) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU730137B2 (en) | 1996-01-24 | 2001-03-01 | H. Lundbeck A/S | DNA encoding galanin GALR2 receptors and uses thereof |
| US6329197B2 (en) | 1996-10-09 | 2001-12-11 | Synaptic Pharmaceutical Corporation | DNA encoding galanin GALR3 receptors and uses thereof |
| CA2459183A1 (en) * | 2001-08-27 | 2003-03-06 | Tularik Inc. | Amplified oncogenes and their involvement in cancer |
| WO2003070950A1 (fr) * | 2002-02-22 | 2003-08-28 | Takeda Chemical Industries, Ltd. | Nouvel adn et utilisation correspondante |
| GB0403509D0 (en) * | 2004-02-17 | 2004-03-24 | Neuro Targets Ltd | Galanin receptors and brain injury |
| JP2008517930A (ja) * | 2004-10-21 | 2008-05-29 | トランス テック ファーマ，インコーポレイテッド | ＧａｌＲ１のアゴニストとしてのビススルホンアミド化合物、組成物、及び使用法 |
| GB0523550D0 (en) | 2005-11-18 | 2005-12-28 | Hunter Fleming Ltd | Therapeutic uses of steroidal compounds |
| AU2008207287A1 (en) * | 2007-01-19 | 2008-07-24 | Howard Florey Institute Of Experimental Physiology And Medicine | Use of galanin in a method of treating neurodegenerative diseases or conditions |
| WO2009033739A2 (en) * | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
| JP2012501977A (ja) * | 2008-09-09 | 2012-01-26 | モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト | 治療剤としてのペプチドの使用 |
| ES2883838A1 (es) * | 2020-06-04 | 2021-12-09 | Univ Malaga | Prevencion y/o tratamiento del deterioro cognitivo asociado a sindromes de demencia |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1350792A (en) * | 1991-01-16 | 1992-08-27 | General Hospital Corporation, The | Human galanin |
| WO1992015015A1 (en) * | 1991-02-25 | 1992-09-03 | Zymogenetic, Inc. | Methods for detecting galanin antagonists |
| EP0587571B1 (en) * | 1991-03-06 | 1998-05-27 | Garvan Institute Of Medical Research | HUMAN GALANIN, cDNA CLONES ENCODING HUMAN GALANIN AND A METHOD OF PRODUCING HUMAN GALANIN |
| SE9101472D0 (sv) * | 1991-05-15 | 1991-05-15 | Trion Forskning & Utveckling | Galanin antagonist |
| JPH06172387A (ja) * | 1992-12-11 | 1994-06-21 | Aibaitsu Kk | 合成ペプチド誘導体 |
| US6225282B1 (en) * | 1996-01-05 | 2001-05-01 | Genentech, Inc. | Treatment of hearing impairments |
| AU730137B2 (en) * | 1996-01-24 | 2001-03-01 | H. Lundbeck A/S | DNA encoding galanin GALR2 receptors and uses thereof |
-
1997
- 1997-07-24 GB GB9901264A patent/GB2331301C/en not_active Expired - Fee Related
- 1997-07-24 PT PT97932939T patent/PT918455E/pt unknown
- 1997-07-24 JP JP10506711A patent/JP2000516212A/ja not_active Ceased
- 1997-07-24 DK DK02028584.7T patent/DK1342410T3/da active
- 1997-07-24 DE DE69739760T patent/DE69739760D1/de not_active Expired - Lifetime
- 1997-07-24 DE DE69721005T patent/DE69721005T2/de not_active Expired - Lifetime
- 1997-07-24 AT AT02028584T patent/ATE457125T1/de not_active IP Right Cessation
- 1997-07-24 DK DK97932939T patent/DK0918455T3/da active
- 1997-07-24 AU AU36302/97A patent/AU3630297A/en not_active Abandoned
- 1997-07-24 EP EP97932939A patent/EP0918455B1/en not_active Expired - Lifetime
- 1997-07-24 ES ES02028584T patent/ES2340984T3/es not_active Expired - Lifetime
- 1997-07-24 US US09/230,463 patent/US20030009777A1/en not_active Abandoned
- 1997-07-24 WO PCT/GB1997/001991 patent/WO1998003059A1/en active IP Right Grant
- 1997-07-24 EP EP02028584A patent/EP1342410B1/en not_active Expired - Lifetime
- 1997-07-24 AT AT97932939T patent/ATE237346T1/de not_active IP Right Cessation
- 1997-07-24 ES ES97932939T patent/ES2196349T3/es not_active Expired - Lifetime
- 1997-07-24 PT PT02028584T patent/PT1342410E/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2340984T3 (es) | 2010-06-14 |
| EP1342410A3 (en) | 2003-12-10 |
| ATE237346T1 (de) | 2003-05-15 |
| GB2331301B (en) | 2001-02-14 |
| PT1342410E (pt) | 2010-05-11 |
| GB2331301C (en) | 2005-05-22 |
| DE69721005D1 (de) | 2003-05-22 |
| DE69721005T2 (de) | 2004-06-09 |
| AU3630297A (en) | 1998-02-10 |
| EP0918455B1 (en) | 2003-04-16 |
| DK0918455T3 (da) | 2003-08-04 |
| US20030009777A1 (en) | 2003-01-09 |
| ES2196349T3 (es) | 2003-12-16 |
| DE69739760D1 (de) | 2010-03-25 |
| WO1998003059A1 (en) | 1998-01-29 |
| JP2000516212A (ja) | 2000-12-05 |
| ATE457125T1 (de) | 2010-02-15 |
| GB9901264D0 (en) | 1999-03-10 |
| EP0918455A1 (en) | 1999-06-02 |
| EP1342410B1 (en) | 2010-02-10 |
| EP1342410A2 (en) | 2003-09-10 |
| PT918455E (pt) | 2003-09-30 |
| GB2331301A (en) | 1999-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69925024D1 (de) | Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten | |
| HK1074573A1 (en) | Tetrahydroquinoline analogues as muscarinic agonists | |
| BR0116206A (pt) | Peptìdeo yy e agonistas de peptìdeo yy para tratamento de distúrbios metabólicos | |
| AP2001002129A0 (en) | 5HT1 receptor agonists and metoclopramide for the treatment of migrane. | |
| HK1123741A1 (en) | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders (dextromethorphan)(quinidine) | |
| ATE396973T1 (de) | Benzylether- und benzylamino-beta-sekretase- hemmer zur behandlung von alzheimer-krankheit | |
| ATE363290T1 (de) | Cd40 antagonist zur behandlung von psoriasis | |
| DK1342410T3 (da) | Anvendelse af en galaninagonist til fremstilling af et medikament til forbedring af hukommelse og andre kognitive funktioner | |
| EA200301253A1 (ru) | Применение остеопонтина для лечения и/или профилактики неврологических заболеваний | |
| YU13301A (sh) | Muskarinski agonisti i antagonisti | |
| MY133503A (en) | Selective iglur5 receptor antagonists for the treatment of migrane | |
| PL350568A1 (en) | N-(2-phenyl-4-aminobutyl)-1-naphtamides as antagonists of neurokinin 1 receptors | |
| AU5548801A (en) | Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies | |
| IT1293804B1 (it) | Diarilalchilpiperazine attive sulle basse vie urinarie | |
| AU2002212441A1 (en) | Use of vanilloid 4 receptor and antagonists or agonists thereof for treating diseases associated with pain | |
| ATE407925T1 (de) | 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen | |
| AR010304A1 (es) | Compuestos de dimesilato de cis-1-(3-etoxifenil)-1-4-fenilpiperazin-1-il) -4-metilciclohexano; procedimiento para su preparacion y composicionfarmaceutica | |
| ATE333287T1 (de) | Prophylaxe und behandlung von autoimmunen entmyelinisierungserkrankungen durch fas- antagonisten | |
| EA200200656A1 (ru) | НОВЫЕ ТЕРАПЕВТИЧЕСКИЕ КОМБИНАЦИИ (S)-2-(БЕНЗИЛАМИНОМЕТИЛ)-2,3,8,9-ТЕТРАГИДРО-7H-1,4-ДИОКСИН [2,3-е]ИНДОЛ-8-ОНА И НЕЙРОЛЕПТИКОВ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРЕДОТВРАЩЕНИЯ ПСИХОТИЧЕСКИХ РАССТРОЙСТВ | |
| ATE402147T1 (de) | 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen | |
| DE69941134D1 (de) | Verwendung von R (+)- g(a)-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol zur Behandlung von Schlafstörungen | |
| UA33242A (uk) | Пристрій для фіксації та обробки ниркових трансплантатів |